PRAC concludes review of signal of increased risk of major cardiovascular events and cancer with tofacitinib (Xeljanz)

PRAC is advising healthcare professionals that tofacitinib should only be used in pts >65 years, those who are current/past smokers, those with other cardiovascular risk factors, and those with other malignancy risk factors, if no suitable treatment alternative is available.

European Medicines Agency